Lincoln Pharma Board Recommends ₹1.80 Dividend, Approves FY26 Results

Lincoln Pharmaceuticals Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The board also recommended a final dividend of ₹1.80 per equity share, representing 18% of the face value, for the financial year ended March 31, 2026. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. For the year ended March 31, 2026, the company reported revenue from operations of ₹67,102.99 Lakhs and a net profit of ₹8,789.38 Lakhs.